Related Experiment Videos
Toxin-labeled monoclonal antibodies.
1Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Current Pharmaceutical Biotechnology
|January 5, 2002
Summary
Monoclonal antibodies are engineered into immunotoxins to target cancer cells. Newer recombinant immunotoxins show clinical activity in hematologic malignancies with improved safety profiles compared to conventional therapies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Immunotoxins combine monoclonal antibodies (MAbs) with toxins to target and kill malignant cells.
- Conventional immunotoxins face challenges like dose-limiting toxicities such as vascular leak syndrome.
Purpose of the Study:
- To review the development and clinical activity of immunotoxins for cancer therapy.
- To highlight advancements in recombinant immunotoxin design and their potential benefits.
Main Methods:
- Development of conventional immunotoxins via chemical conjugation of MAbs to toxins.
- Engineering of newer recombinant immunotoxins by fusing antibody variable domains (Fv) or growth factors to truncated bacterial toxins (e.g., Pseudomonas exotoxin).
Main Results:
- Conventional immunotoxins have shown efficacy in hematologic malignancies but are associated with significant toxicities.
- Recombinant immunotoxins like LMB-2 and BL22 demonstrate clinical activity with reduced vascular leak syndrome and immunogenicity.
Conclusions:
- Recombinant immunotoxins represent an advancement over conventional immunotoxins, offering improved safety and efficacy.
- Ongoing research focuses on developing novel immunotoxins for both hematologic and solid tumors.